John Divine

John Divine

John Divine is currently an investing reporter at U.S. News & World Report, and was previously an assistant editor at InvestorPlace.com. He has worked variously in the fields of commercial real estate, money management and digital media, working as a financial journalist for most of his professional career.

John has also been a regular contributor to The Motley Fool, and his work also has appeared on AOL DailyFinance.

In 2013, he shortened his bucket list when he saw Warren Buffett live and in the flesh while covering the Berkshire Hathaway Annual Shareholders’ Meeting.

A proud North Carolinian and graduate of Appalachian State University, John majored in Finance & Banking. He enjoys basketball, reading, writing and food. He does not care for the Oxford comma, and he does not require the food he enjoys to be nutritious.

Recent Articles

Is Best Buy (BBY) a Value Stock After Dividend Hike?

Best Buy (BBY) boosted its dividend by 21% and notched a 9th straight quarter beating consensus EPS estimates. Dare we label Best Buy a value stock?

Are These 5 Battered Stocks Doomed Forever — Or Bargain Buys?

These 5 stocks have gotten hammered recently. But which ones are garbage and which ones are truly value plays?

How the HP-Aruba Networks Deal Impacts HPQ Stock

HP is buying Aruba Networks for $2.7 billion in a move giving HPQ stock exposure to enterprise Wi-Fi networks. What should investors think?

GOOG and Android Pay vs. Apple Pay and AAPL

Android Pay, GOOG's new payment API, takes on Apple Pay & AAPL. But what IS Android Pay, how does it threaten Apple, and where does Google Wallet fit in?

GOOG Puts Cash to Work in $300 Million SCTY Deal

Google (GOOG) and SolarCity (SCTY) struck a $300 million deal Thursday. Here's why the tax-equity venture is bullish for both stocks.

MNST Stock: The Best Growth Stock to Buy For 2015?

MNST stock is rocketing higher on Friday after Monster earnings crushed expectations. Here's why it could be the best growth stock to buy for 2015.

BSX Stock a Strong Buy After $600 Million Guidant Settlement

Even after a nice run-up in the Boston Scientific (BSX) stock price, shares are a steal, thanks to the $600 million Guidant settlement.

Sanofi (SNY) Stock: One Big Bet on Diabetes Drugs

Sanofi (SNY) stock faces downward pressure as its flagship diabetes drug Lantus goes off market. Will Toujeo and Afrezza be enough to stem the bleeding?

BKS Stock Still Doomed After College Spinoff Plans

Barnes & Noble (BKS) stock is up today after announcing a spinoff of its college bookstore business. I'm afraid it's too little, too late for this company.

Why Is DISH Stock Massively Overvalued?

DISH stock, while rewarding its recent investors, could crush those who pile into it now. Here's why Wall Street is overvaluing the pay-TV provider.